套细胞淋巴瘤风险适应治疗时机已到
套细胞淋巴瘤治疗选择多但难以治愈,复发常见且副作用严重,当前推荐主要基于年龄而非生物学特征。TP53突变或缺失、母细胞样组织学和高Ki-67增殖指数可识别高复发风险患者,可测量残留病阳性是识别治疗反应不足患者的有效替代终点。文章呼吁细化风险分层、统一治疗并整合多参数生物标志物以改善预后。
要点
- TP53突变/缺失、母细胞样组织学和高Ki-67指数可识别高复发风险患者。
- 可测量残留病阳性可作为识别治疗反应不足患者的替代终点。
- 基于年龄而非生物学的非风险适应治疗已过时,需细化风险分层。
核心结论
- 套细胞淋巴瘤需从基于年龄的治疗转向基于生物学特征的风险适应治疗。
研究设计与样本
- 本文为Lancet Haematol发表的综述/观点文章,未报告系统检索范围与样本量。
主要发现
- TP53突变或缺失、母细胞样组织学和高Ki-67增殖指数一致识别高复发风险患者。
- 可测量残留病阳性是识别治疗反应不足患者的强效替代终点。
- 惰性套细胞淋巴瘤标志物、毒性和耐受性标志物需进一步细化,可能允许无化疗方案。
临床怎么用
- 临床应整合TP53状态、组织学和Ki-67指数进行风险分层,并利用可测量残留病指导治疗调整。
局限性
- 本文为观点/综述类文章,未报告原始研究数据、阈值或疗效数值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mantle cell lymphoma has multiple treatment options, yet the disease is difficult to cure. Relapses are common, treatments can cause severe side-effects, and current recommendations are still largely based on age rather than biology. Although suitability for intensive treatment was previously the decisive parameter, increasing knowledge on the biology of mantle cell lymphoma and less toxic targeted therapies has made non-risk adapted treatments outdated. TP53 mutations or deletions, blastoid histology, and a high Ki-67 proliferation index consistently identify patients at high risk of relapse. Additionally, positive measurable residual disease serves as a powerful surrogate endpoint to identify patients with an inadequate treatment response who might benefit from treatment modification. Similarly, markers of indolent mantle cell lymphoma, toxicity, and tolerability need to be further refined and might permit chemotherapy-free approaches. We outline future initiatives aimed at refining risk stratification, harmonising treatment, and integrating multiparameter biomarkers to improve prognosis and provide the biological rational for combination strategies. These efforts are essential to accelerate the translation of biological insights into clinical practice.
引用
- Glimelius I, Nikkarinen A, Meriranta L, et al. High time for risk-adapted treatment in mantle cell lymphoma. Lancet Haematol. 2026. PMID: 42685741. doi:10.1016/S2352-3026(26)00127-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。